Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(56%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
6
67%

Phase Distribution

0

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
6(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(1)
Other(3)

Detailed Status

Recruiting5
unknown3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 26 (100.0%)

Trials by Status

recruiting556%
completed111%
unknown333%

Recent Activity

5 active trials
Showing 5 of 9
recruitingphase_2

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

NCT07117630
recruitingphase_2

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

NCT06145308
recruitingphase_2

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

NCT07472140
recruitingphase_2

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

NCT05200260
unknown

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

NCT04724031
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07117630Phase 2

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Recruiting
NCT06145308Phase 2

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting
NCT07472140Phase 2

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Recruiting
NCT05200260Phase 2

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Recruiting
NCT04724031

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Unknown
NCT05406999Phase 2

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Recruiting
NCT05392686Phase 2

PD1 and PARP for Maintenance Therapy in NSLLC

Unknown
NCT04774627

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Completed
NCT05044091

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9